Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial
Standard
Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial. / Mandel, Philipp C; Huland, Hartwig; Tiebel, Anne; Haese, Alexander; Salomon, Georg; Budäus, Lars; Tilki, Derya; Chun, Felix; Heinzer, Hans; Graefen, Markus; Pantel, Klaus; Riethdorf, Sabine; Steuber, Thomas.
in: EUR UROL FOCUS, Jahrgang 7, Nr. 1, 01.2021, S. 55-62.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial
AU - Mandel, Philipp C
AU - Huland, Hartwig
AU - Tiebel, Anne
AU - Haese, Alexander
AU - Salomon, Georg
AU - Budäus, Lars
AU - Tilki, Derya
AU - Chun, Felix
AU - Heinzer, Hans
AU - Graefen, Markus
AU - Pantel, Klaus
AU - Riethdorf, Sabine
AU - Steuber, Thomas
N1 - Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - BACKGROUND: The prognostic value of circulating tumor cells (CTCs) in patients with hormone-naïve oligometastatic prostate cancer (HNoMPC) undergoing cytoreductive radical prostatectomy (CRP) is unknown.OBJECTIVE: To determine the pre- and postoperative prognostic value of CTC enumeration in patients undergoing CRP.DESIGN, SETTING, AND PARTICIPANTS: Thirty-three patients with HNoMPC from the prospective, single-arm ProMPT trial who underwent CRP between 2014 and 2015 at the Martini-Klinik were evaluated. Follow-up visits for all patients were conducted every 6 mo up to 36 mo after CRP and included serial detection of CTCs in 7.5 ml blood samples using the CellSearch system.INTERVENTION: CRP.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: CTC enumerations before and after CRP, and their prognostic value on metastatic castration-resistant prostate cancer-free survival and overall survival (OS) were analyzed using Kaplan-Meier plots and univariable Cox-regression analysis.RESULTS AND LIMITATIONS: Sixteen patients (48.5%) had positive CTCs prior to CRP. A CTC count of ≥2 before or 6 mo after CRP was a prognostic factor for worse oncologic outcome. Compared with other biomarkers (prostate-specific antigen, lactate dehydrogenase, and bone-specific alkaline phosphatase), the prognostic value of CTCs was highest using Harrell's C for OS (0.69), while the highest C-index could be achieved for a combination of conventional markers and CTC count (0.74). After progression to metastatic castration-resistant prostate cancer, CTC enumeration of ≥5 was prognostic for OS. The main limitation is the small sample size.CONCLUSIONS: CTC enumeration contributes to prognostic information, which might help select HNoMPC patients who might benefit most from CRP.PATIENT SUMMARY: In this report, we looked at the value of circulating tumor cell (CTC) determination in patients undergoing radical prostatectomy for oligometastatic prostate cancer. We could show that the number of CTCs was a prognostic factor at all analyzed time points and was more closely associated with prognosis than other biomarkers commonly used in daily clinical practice.
AB - BACKGROUND: The prognostic value of circulating tumor cells (CTCs) in patients with hormone-naïve oligometastatic prostate cancer (HNoMPC) undergoing cytoreductive radical prostatectomy (CRP) is unknown.OBJECTIVE: To determine the pre- and postoperative prognostic value of CTC enumeration in patients undergoing CRP.DESIGN, SETTING, AND PARTICIPANTS: Thirty-three patients with HNoMPC from the prospective, single-arm ProMPT trial who underwent CRP between 2014 and 2015 at the Martini-Klinik were evaluated. Follow-up visits for all patients were conducted every 6 mo up to 36 mo after CRP and included serial detection of CTCs in 7.5 ml blood samples using the CellSearch system.INTERVENTION: CRP.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: CTC enumerations before and after CRP, and their prognostic value on metastatic castration-resistant prostate cancer-free survival and overall survival (OS) were analyzed using Kaplan-Meier plots and univariable Cox-regression analysis.RESULTS AND LIMITATIONS: Sixteen patients (48.5%) had positive CTCs prior to CRP. A CTC count of ≥2 before or 6 mo after CRP was a prognostic factor for worse oncologic outcome. Compared with other biomarkers (prostate-specific antigen, lactate dehydrogenase, and bone-specific alkaline phosphatase), the prognostic value of CTCs was highest using Harrell's C for OS (0.69), while the highest C-index could be achieved for a combination of conventional markers and CTC count (0.74). After progression to metastatic castration-resistant prostate cancer, CTC enumeration of ≥5 was prognostic for OS. The main limitation is the small sample size.CONCLUSIONS: CTC enumeration contributes to prognostic information, which might help select HNoMPC patients who might benefit most from CRP.PATIENT SUMMARY: In this report, we looked at the value of circulating tumor cell (CTC) determination in patients undergoing radical prostatectomy for oligometastatic prostate cancer. We could show that the number of CTCs was a prognostic factor at all analyzed time points and was more closely associated with prognosis than other biomarkers commonly used in daily clinical practice.
U2 - 10.1016/j.euf.2019.05.008
DO - 10.1016/j.euf.2019.05.008
M3 - SCORING: Journal article
C2 - 31178293
VL - 7
SP - 55
EP - 62
JO - EUR UROL FOCUS
JF - EUR UROL FOCUS
SN - 2405-4569
IS - 1
ER -